SCHEMBL3847566

SCHEMBL3847566

CC(C)(C)OC(=O)N1CCCC1C(=O)C=Cc1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
NPC1 O15118 2/20 0.47
HRH3 Q9Y5N1 1/20 0.47
LMNA P02545 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTT P42858 1/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
HSD17B10 Q99714 1/20 0.45
UCHL1 P09936 2/20 0.44
USP30 Q70CQ3 2/20 0.44
POLB P06746 2/20 0.44
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13375890 1.00 ALDH1A1 (0.53) ALDH1A1NPC1HRH3LMNANPSR1
SCHEMBL3847565 1.00 ALDH1A1 (0.53) ALDH1A1NPC1HRH3LMNANPSR1
SCHEMBL3887005 0.84 ALDH1A1 (0.52) ALDH1A1NPC1LMNANPSR1HTT
SCHEMBL3887009 0.84 ALDH1A1 (0.52) ALDH1A1NPC1LMNANPSR1HTT
SCHEMBL3887013 0.84 ALDH1A1 (0.52) ALDH1A1NPC1LMNANPSR1HTT
SCHEMBL14261834 0.82 HSD17B10 (0.56) ALDH1A1NPC1LMNANPSR1MEN1
SCHEMBL1429462 0.80 NPC1 (0.58) ALDH1A1NPC1LMNANPSR1MEN1
SCHEMBL1429465 0.80 NPC1 (0.58) ALDH1A1NPC1LMNANPSR1MEN1
SCHEMBL18589370 0.80 NPC1 (0.58) ALDH1A1NPC1LMNANPSR1MEN1
SCHEMBL13374884 0.78 PREP (0.53) ALDH1A1LMNANPSR1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288371-B2 Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation PHARMACOPEIA, LLC (US) 2012-10-16 US disclosed
WO-2009082526-A2 ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION PHARMACOPEIA, INC. (US) 2009-07-02 WO disclosed
US-20090093472-A1 ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION PHARMACOPEIA, INC. (US) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093472-A1 ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION CCR1, CCR4, CCR3 ALDH1A1 931/4885NPC1 1954/4885HRH3 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.